These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 32963191)

  • 1. [A CASE OF SEVERE ASTHMA SWITCHED TO MEPOLIZUMAB DUE TO LATE-OCCURRING UNRESPONSIVENESS TO BENRALIZUMAB].
    Matsumoto-Sasaki M; Shimizu K; Suzuki M; Suzuki M; Nakamaru Y; Konno S
    Arerugi; 2020; 69(8):678-682. PubMed ID: 32963191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study.
    Numata T; Miyagawa H; Nishioka S; Okuda K; Utsumi H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
    BMC Pulm Med; 2020 Aug; 20(1):207. PubMed ID: 32746787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of eosinophilic chronic rhinosinusitis in switching to benralizumab treatment in mepolizumab responders.
    Hamada S; Kobayashi Y; Yasuba H
    Int J Clin Pharmacol Ther; 2020 Dec; 58(12):703-708. PubMed ID: 32831163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies.
    Goldman M; Hirsch I; Zangrilli JG; Newbold P; Xu X
    Curr Med Res Opin; 2017 Sep; 33(9):1605-1613. PubMed ID: 28644104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL13 May Play an Important Role in Developing Eosinophilic Chronic Rhinosinusitis and Eosinophilic Otitis Media with Severe Asthma.
    Shimizu H; Hayashi M; Kato H; Nakagawa M; Imaizumi K; Okazawa M
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis.
    Tsurumaki H; Matsuyama T; Ezawa K; Koga Y; Yatomi M; Aoki-Saito H; Chikamatsu K; Hisada T
    Medicina (Kaunas); 2019 Jul; 55(7):. PubMed ID: 31277327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis.
    Numata T; Nakayama K; Utsumi H; Kobayashi K; Yanagisawa H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
    BMC Pulm Med; 2019 Oct; 19(1):176. PubMed ID: 31606052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of eosinophilic chronic rhinosinusitis and eosinophilic otitis media using the anti-IL-5 receptor monoclonal antibody benralizumab: A case report.
    Kagoshima H; Hori R; Kojima T; Okanoue Y; Taguchi A; Yamamoto H; Hasebe K; Shoji K
    Respir Med Case Rep; 2020; 30():101135. PubMed ID: 32612919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Sinonasal Histopathological Changes in Biological Treatment of Eosinophilic Chronic Rhinosinusitis.
    Ho J; Alvarado R; Rimmer J; Sewell WA; Walter S; Earls P; Campbell RG; Sacks R; Kalish LH; Harvey RJ
    Am J Rhinol Allergy; 2022 Jan; 36(1):72-80. PubMed ID: 34096329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma.
    Lombardo N; Pelaia C; Ciriolo M; Della Corte M; Piazzetta G; Lobello N; Viola P; Pelaia G
    Int J Immunopathol Pharmacol; 2020; 34():2058738420950851. PubMed ID: 32816558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matching-adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics.
    Bourdin A; Husereau D; Molinari N; Golam S; Siddiqui MK; Lindner L; Xu X
    Clin Exp Allergy; 2020 Apr; 50(4):442-452. PubMed ID: 31943429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benralizumab and mepolizumab treatment outcomes in two severe asthma clinics.
    Langton D; Politis J; Collyer T; Khung SW; Bardin P
    Respirology; 2023 Dec; 28(12):1117-1125. PubMed ID: 37638723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience.
    Scioscia G; Tondo P; Nolasco S; Pelaia C; Carpagnano GE; Caiaffa MF; Valenti G; Maglio A; Papia F; Triggiani M; Crimi N; Pelaia G; Vatrella A; Foschino Barbaro MP; Crimi C
    J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
    Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of benralizumab in a patient with uncontrolled severe eosinophilic asthma and comorbid chronic rhinosinusitis with nasal polyps refractory to mepolizumab treatment.
    Mansur AH
    Respir Med Case Rep; 2022; 35():101559. PubMed ID: 34976716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-Life Effectiveness of Benralizumab, Mepolizumab and Omalizumab in Severe Allergic Asthma Associated with Nasal Polyps.
    Tiotiu A; Mendez-Brea P; Ioan I; Romero-Fernandez R; Oster JP; Hoang TC; Roux P; Ochoa-Gutierrez DC; Bonniaud P; de Blay F; Gonzalez-Barcala FJ
    Clin Rev Allergy Immunol; 2023 Apr; 64(2):179-192. PubMed ID: 35420388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
    Busse W; Chupp G; Nagase H; Albers FC; Doyle S; Shen Q; Bratton DJ; Gunsoy NB
    J Allergy Clin Immunol; 2019 Jan; 143(1):190-200.e20. PubMed ID: 30205189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
    Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
    Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis.
    Takabayashi T; Asaka D; Okamoto Y; Himi T; Haruna S; Yoshida N; Kondo K; Yoshikawa M; Sakuma Y; Shibata K; Suzuki M; Kobayashi M; Kawata R; Tsuzuki K; Okano M; Higaki T; Takeno S; Kodama S; Yonekura S; Saito H; Nozaki A; Otori N; Fujieda S
    Am J Rhinol Allergy; 2021 Nov; 35(6):861-870. PubMed ID: 33840229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benralizumab: an anti-IL-5 receptor α monoclonal antibody in the treatment of asthma.
    Kupczyk M; Kuna P
    Immunotherapy; 2018 Apr; 10(5):349-359. PubMed ID: 29359607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.